Boehringer Ingelheim’s Post

This landmark strategic partnership between Brainomix and Boehringer Ingelheim paves the way to transform the diagnosis and treatment of patients with fibrosing lung disease. If these patients are untreated, they have a life expectancy worse than cancer and yet despite this, they often have to wait up to 2 years for diagnosis. With our AI-powered imaging biomarkers in e-Lung, we are aiming to change this by bringing forward diagnosis decisions and giving access to treatments earlier, improving patient outcomes. It is through such partnerships that we have achieved clinical impact at scale in stroke and now our mission is to replicate this success in fibrosing lung disease. #eLung #ai #fibrosinglungdisease #BI #partnership #USA #lung #Brainomix360 #BoehringerIngelheim

Behind this annoucement, there are two critical learnings from companies focusing in AI in medical imaging. 1. Imaging biomarkers powered by AI aim to be the ‘companion diagnostic test’ for treatment decision. Lifescience companies already see a strong potential for precise medicine there. 2. Aside from technology advances (AI) and go-to-market functions, the translational medicine function in an AI company builds the necessary bridge between early clinical signals from technology, real clinical use case (would it make a difference from patient outcomes?) and real-world evidence that can only make technology finally relevant for Lifescience, health systems and patients.

Brainomix and Boehringer Ingelheim Launch Strategic Partnership in Fibrosing Lung Disease The project will evaluate the real-world impact of Brainomix's e-Lung imaging software to improve the identification and access to treatment for people with progressive pulmonary fibrosis in the US. Michalis Papadakis: "There is an urgent need to improve the identification of people with fibrosing lung disease. This will enable earlier access to specialist care and the opportunity for faster initiation of treatment, which can slow the worsening of the disease. The patient pathway for people with fibrosing lung disease is currently fragmented and it can take many years for a patient to be diagnosed. "This partnership enables us to leverage our established experience and expertise connecting stroke networks to develop a similar network model of care for patients with fibrosing lung disease, generating real-world evidence that will drive the opportunities we have with e-Lung to help improve outcomes for patients and their families." Read more about this partnership: ⬇ https://lnkd.in/eFhtvQhE Boehringer Ingelheim #eLung #ai #fibrosinglungdisease #BI #partnership #USA #lung #Brainomix360

AI-powered imaging biomarkers applied to Lifescience: in layman terms, clinicians can get precise insights on the existence of a devasting medical condition (descriptive analytics) and on the evolution of this disease (predictive analytics)…a major milestone for better patient outcomes in the case of lung fibrosis…developed by Brainomix and supported by a leading Pharmaceutical company!

Boehringer Ingelheim and Brainomix have entered into a strategic partnership for a collaborative programme to improve the identification and access to treatment for people living with fibrosing lung disease in the US. The project will evaluate the real-world impact of Brainomix’s 360 e-Lung imaging software for patients with progressive pulmonary fibrosis (PF). Affecting up to 20 out of every 100,000 people worldwide, including 100,000 people in the US, according to the National Institutes of Health, PF is a progressive, chronic lung condition that leads to difficulty breathing and shortness of breath. For the best outcomes for patients, early initiation of treatment can help prevent or delay progression. However, identifying patients eligible for treatment based on imaging can be challenging. The project will focus on the use of artificial intelligence imaging analysis using Brainomix’s software on routine CT scans to accelerate diagnosis and improve access to treatment by deploying it to leading US pulmonology centres and their networks of referring sites. The data generated will validate the value of e-Lung as well as its potential to optimise pathways of care and improve outcomes for people living with the condition through digital technology. The e-Lung software received clearance from the US Food and Drug Administration in May 2024 and Brainomix recently announced a new series of studies to highlight its prognostic value in patients with fibrotic lung disease. Ioannis Sapountzis, head of global therapeutic areas, Boehringer Ingelheim, said: “We believe that Brainomix 360 e-Lung has the potential to revolutionise the diagnostic landscape and thereby enable earlier treatment decisions…, ultimately improving patient outcomes and quality of life of those affected.” Read more: https://lnkd.in/eYEvhmzZ

Excited to share insights from our latest publication unveiling Noselab's innovative diagnostic platform for #Alzheimer's disease (AD). Presented at the prestigious AD/PD - Advances in Science & Therapy 2024 conference in Lisbon. Our approach focuses on detecting AD biomarkers derived from the upper nasal cavity for safe and non-invasive diagnosis. By analyzing nasal cerebrospinal fluid (#nCSF) collected from the vicinity of the brain-nose interface (BNI), our platform offers a promising solution for early-stage detection and patient stratification. Traditional methods like PET scans and CSF assays often pose accessibility and invasiveness challenges, which our methodology aims to overcome. With an initial focus on AD, our platform offers a comprehensive solution for patient assessment and monitoring. Beyond AD, our approach holds promise for detecting other neurodegenerative diseases, potentially transforming the diagnostic landscape. With the potential to revolutionize AD diagnostics, we're committed to advancing patient care and research in neurodegenerative diseases. #AlzheimersResearch #InnovationInHealthcare #MedicalBreakthroughs https://lnkd.in/eGNfFgEN

Endotyping for lung fibrosis

New Publication: Our recent paper reviews the diagnostic value of imaging and serological biomarkers in pulmonary sarcoidosis. This study highlights the importance of these biomarkers in clinical diagnosis, disease activity assessment, and prognosis. Free to view and download at: https://lnkd.in/dbEtQ4M3. #Sarcoidosis #Biomarkers #Imaging #ClinicalDiagnosis

Hello everyone, I’m thrilled to share our latest publication on exosomes and cardiomyopathies. Exosomes, small extracellular vesicles vital for intercellular communication, show great promise in diagnosing and treating cardiomyopathies. Their role in diseases like dilated, restrictive, arrhythmogenic, and hypertrophic cardiomyopathy highlights their potential as both diagnostic biomarkers and therapeutic targets. A deeper understanding of how exosomes affect disease progression could lead to better diagnosis and treatment strategies, ultimately improving patient outcomes. However, further research is needed to unlock their full clinical potential. Check out our Open Access article published in Life Science through the link below! #exosomes #cardiomyopathies #diagnosis #biomarkers #treatment

Timely diagnosis Alzheimer's disease is crucial for patient outcomes, yet current diagnostics methods, though effective, such as CSF, are often invasive and costly. The promising path forward? Blood-based biomarkers. 🩸 #Alzheimers #BloodBiomarkers #EarlyDiagnosis